ISB News

ISB Gets $1.7M to Study Cancer Drug Resistance

Congratulations to the Sui Huang Lab at ISB which has received a five-year $1.7 million R01 award from the National Institutes of Health and National Institute for General Medical Sciences to study cancer sub-population dynamics to understand and develop drugs to inhibit lethal cancer-drug resistance. The project proposal states that the work will: “develop a quantitative and formal framework for describing the temporal evolution of cell phenotype distribution in a tumor cell population to address the unmet need to understand how heterogeneity and subpopulation dynamics of tumor cell populations affect drug response.”

Learn more:

Cancer Treatment: A Systems Approach

New Principle of Chemo-Resistance Sheds Light on Cancer Evasiveness

Biggest Family Tree of Human Cells May Help Develop Cell-Replacement Therapies

 


 

Recent Articles

  • Building a Better BMI

    ISB researchers have constructed biological body mass index (BMI) measures that offer a more accurate representation of metabolic health and are more varied, informative and actionable than the traditional, long-used BMI equation. The work was published in the journal Nature Medicine. 

  • How Immune Cells ‘See’ and Respond to Mutations in Cancer Cells

    In a just-published paper in the journal Nature, a collaborative team of researchers from ISB, UCLA, PACT Pharma, and beyond analyzed T-cell responses in melanoma patients who were treated with different immune checkpoint inhibitors, and how those responses evolved over time.

  • Spotlight on ISB Education graphic

    2022-23 School Year ISB Education Highlights

    From planning, creating and executing workshops for educators to forging new relationships to elevate students, the ISB Education team has been in high gear. Each month throughout the 2022-2023 academic year, we will highlight some of the top projects the team is working on.